3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
tegaserod
3
naloxegol
3
Radiotherapy
3
Cisplatin
3
Surveys and Questionnaires
2
Radiation
2
Lidocaine
2
prucalopride
1
pegfilgrastim
1
oxycodone naloxone combination
1
indole-3-carbinol
1
hydrated silica gel-based toothpaste
1
glucarpidase
1
angiotensin I (1-7)
1
alvimopan
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Vitamin D
1
Transcutaneous Electric Nerve Stimulation
1
Thyrotropin-Releasing Hormone
1
Tablets
1
Surgical Procedures, Operative
1
Sennosides
1
Selenomethionine
1
Phenolphthalein
1
Observation
1
Nutrition Assessment
1
Neck Dissection
1
Methotrexate
1
Methods
1
Metformin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
angiotensin I (1-7)
×
Other
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled